| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Benjamin Voellger, Zhuo Zhang, Julia Benzel, Junwen Wang, Ting Lei, Christopher Nimsky, Jörg-Walter Bartsc. Targeting Aggressive Pituitary Adenomas at the Molecular Level-A Review. Journal of clinical medicine. vol 11. issue 1. 2022-01-11. PMID:35011868. |
dopamine agonists (das) are the first line treatment for prolactinomas. |
2022-01-11 |
2023-08-13 |
human |
| Jeong-Hwa Kim, Kyu-Yeon Hur, Sang-Duk Hong, Jung-Won Choi, Ho-Jun Seol, Do-Hyun Nam, Jung-Il Lee, Doo-Sik Kon. Serum prolactin level to tumor size ratio as a potential parameter for preoperative differentiation of prolactinomas from hyperprolactinemia-causing non-functional pituitary adenomas. World neurosurgery. 2021-12-27. PMID:34958988. |
preoperative diagnosis of prolactinomas is critical because dopamine agonists have been regarded as a primary treatment. |
2021-12-27 |
2023-08-13 |
Not clear |
| Ozge Telci Caklili, Ayse Merve Ok, Zulal Istemihan, Ozlem Selcukbiricik, Sema Yarma. Optimal testosterone level to improve symptoms of hypogonadism without causing dopa-testotoxicosis in male macroprolactinoma. Annales d'endocrinologie. 2021-12-06. PMID:34871603. |
male prolactinoma treatment by dopamine agonists (da) restores sexual function. |
2021-12-06 |
2023-08-13 |
Not clear |
| Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu W. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. BMC endocrine disorders. vol 21. issue 1. 2021-11-30. PMID:34814904. |
the role of mapk11/12/13/14 (p38 mapk) protein in dopamine agonist-resistant prolactinomas. |
2021-11-30 |
2023-08-13 |
Not clear |
| Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu W. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. BMC endocrine disorders. vol 21. issue 1. 2021-11-30. PMID:34814904. |
dopamine agonists (das) such as bromocriptine (brc) are the first-line treatment for prolactinomas, but the resistance rate is increasing year by year, creating a clinical challenge. |
2021-11-30 |
2023-08-13 |
Not clear |
| Shuman Wang, Aihua Wang, Yu Zhang, Kejing Zhu, Xiong Wang, Yonggang Chen, Jinhu W. The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas. BMC endocrine disorders. vol 21. issue 1. 2021-11-30. PMID:34814904. |
our previous studies have demonstrated that inhibiting mapk14 can suppress the occurrence of prolactinoma, but the role of mapk11/12/13/14 (p38 mapk) signalling in dopamine agonist-resistant prolactinomas is still unclear. |
2021-11-30 |
2023-08-13 |
Not clear |
| Camille Hage, Roberto Salvator. Speed of response to dopaminergic agents in prolactinomas. Endocrine. 2021-11-30. PMID:34846682. |
the objective of this work was to determine the response to dopamine agonists (das) in bona fide prolactinomas presenting with a prolactin range similar to what can be seen in nonhormonal secreting pituitary tumors. |
2021-11-30 |
2023-08-13 |
Not clear |
| Junhao Zhu, Chao Tang, Zixiang Cong, Feng Yuan, Xiangming Cai, Jin Yang, Chiyuan M. ACT001 reverses resistance of prolactinomas via AMPK-mediated EGR1 and mTOR pathway. Endocrine-related cancer. 2021-11-25. PMID:34821219. |
dopamine agonist (da) is the first choice for the treatment of prolactinomas and drug resistance is unavoidable during treatment due to the heterogeneity of tumors. |
2021-11-25 |
2023-08-13 |
Not clear |
| Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jian. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders. vol 21. issue 1. 2021-11-18. PMID:34774043. |
the recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. |
2021-11-18 |
2023-08-13 |
Not clear |
| Yunzhi Zou, Depei Li, Jiayu Gu, Siyu Chen, Xia Wen, Jiajun Dong, Xiaobing Jian. The recurrence of prolactinoma after withdrawal of dopamine agonist: a systematic review and meta-analysis. BMC endocrine disorders. vol 21. issue 1. 2021-11-18. PMID:34774043. |
prolactinoma is the major cause of hyperprolactinemia, and dopamine agonists (das) are generally the first-line treatment for them. |
2021-11-18 |
2023-08-13 |
Not clear |
| L Andereggen, J Frey, R H Andres, M M Luedi, M El-Koussy, H R Widmer, J Beck, L Mariani, R W Seiler, E Chris. First-line surgery in prolactinomas: lessons from a long-term follow-up study in a tertiary referral center. Journal of endocrinological investigation. vol 44. issue 12. 2021-11-17. PMID:33847973. |
although consensus guidelines recommend dopamine agonists (das) as the first-line approach in prolactinomas, some patients may opt instead for upfront surgery, with the goal of minimizing the need for continuation of das over the long term. |
2021-11-17 |
2023-08-13 |
Not clear |
| Liguang Wei, Xialin We. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study. Hormones (Athens, Greece). vol 20. issue 4. 2021-11-16. PMID:34275094. |
outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study. |
2021-11-16 |
2023-08-13 |
Not clear |
| Liguang Wei, Xialin We. Outcomes of transsphenoidal surgery in dopamine agonist-resistant prolactinomas: a retrospective study. Hormones (Athens, Greece). vol 20. issue 4. 2021-11-16. PMID:34275094. |
dopamine agonists (da) comprise first-line treatment for prolactinomas. |
2021-11-16 |
2023-08-13 |
Not clear |
| Atsushi Ishida, Hiroki Shichi, Hidenori Fukuoka, Naoko Inoshita, Wataru Ogawa, Shozo Yamad. Efficacy of temozolomide combined with capecitabine (CAPTEM) on refractory prolactinomas as assessed using an ex vivo 3D spheroid assay. Pituitary. 2021-11-13. PMID:34773564. |
refractory prolactinomas resistant to dopamine agonists (das) pose a clinical challenge. |
2021-11-13 |
2023-08-13 |
Not clear |
| Kawngwoo Park, Kwang Hyon Park, Hye Ran Park, Jae Meen Lee, Yong Hwy Kim, Dong Young Kim, Tae Bin Won, Sung Hye Kong, Jung Hee Kim, Chan Soo Shin, Sun Ha Pae. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. Journal of Korean medical science. vol 36. issue 15. 2021-11-03. PMID:33876586. |
long-term outcome of microscopic transsphenoidal surgery for prolactinomas as an alternative to dopamine agonists. |
2021-11-03 |
2023-08-13 |
Not clear |
| Kawngwoo Park, Kwang Hyon Park, Hye Ran Park, Jae Meen Lee, Yong Hwy Kim, Dong Young Kim, Tae Bin Won, Sung Hye Kong, Jung Hee Kim, Chan Soo Shin, Sun Ha Pae. Long-term Outcome of Microscopic Transsphenoidal Surgery for Prolactinomas as an Alternative to Dopamine Agonists. Journal of Korean medical science. vol 36. issue 15. 2021-11-03. PMID:33876586. |
although long-term dopamine agonist (da) therapy is recommended as a first-line treatment for prolactinoma, some patients may prefer surgical treatment because of the potential adverse effects of long-term medication, or the desire to become pregnant. |
2021-11-03 |
2023-08-13 |
Not clear |
| Andres Damian, Maria M Pineyro, Adriana Quagliata, Mariana Risso, Paula Montiglia, Ramiro Lima, Omar Alons. World journal of nuclear medicine. vol 20. issue 3. 2021-10-28. PMID:34703398. |
some studies have assessed the expression of dopaminergic dopamine 2 (d2)/3 receptors in prolactinomas and nonfunctioning pituitary adenomas (nfpa) by positron emission tomography/computed tomography (pet/ct) with |
2021-10-28 |
2023-08-13 |
Not clear |
| Ji Yong Park, Wonsuk Choi, A Ram Hong, Jee Hee Yoon, Hee Kyung Kim, Woo-Youl Jang, Shin Jung, Ho-Cheol Kan. Surgery is a safe, effective first-line treatment modality for noninvasive prolactinomas. Pituitary. vol 24. issue 6. 2021-10-27. PMID:34189717. |
dopamine agonists (das) have long been the recommended first-line treatment for prolactinoma. |
2021-10-27 |
2023-08-13 |
Not clear |
| Frederic Castinetti, Frederique Albarel, Vincent Amodru, Thomas Cuny, Henry Dufour, Thomas Graillon, Isabelle Morange, Thierry Bru. The risks of medical treatment of prolactinoma. Annales d'endocrinologie. vol 82. issue 1. 2021-10-26. PMID:33373604. |
first-line treatment of prolactinoma is usually medical, based on dopamine agonists receptors, mainly cabergoline. |
2021-10-26 |
2023-08-13 |
Not clear |
| Kyla Wright, Matthew Lee, Natalie Escobar, Donato Pacione, Matthew Young, Girish Fatterpekar, Nidhi Agrawa. Tumor volume improves preoperative differentiation of prolactinomas and nonfunctioning pituitary adenomas. Endocrine. vol 74. issue 1. 2021-10-25. PMID:33966173. |
distinguishing them is critical because prolactinomas are effectively managed with dopamine agonists, whereas compressive nfas are treated surgically. |
2021-10-25 |
2023-08-13 |
Not clear |